Wearable Sensor May Detect Hidden Heart Damage After Surgery

McMaster University

Hamilton, ON, Nov. 18, 2026 – Researchers at McMaster University have developed a wearable device that could help detect silent heart injury in the days after surgery, offering a new way to monitor patients after they leave the hospital.

The technology continuously measures cardiac troponin, a protein released when the heart is injured, using a patch equipped with tiny, painless microneedles that sample fluid beneath the skin. The findings were published today in the journal Science Advances .

The work addresses a significant challenge in post-surgical care. About 300 million people undergo non-cardiac surgery each year, and increasing numbers of people are discharged home the same day.

But the days immediately following surgery remain a period of elevated risk, with about 20 per cent of higher risk patients experiencing myocardial injury after non-cardiac surgery, or MINS. Most of these cases occur without obvious symptoms.

"About 90 per cent of these cases are silent. The only way to diagnose many of them is through a blood test, which is difficult when patients are already home," explains Leyla Soleymani, professor of engineering physics and lead of engineering innovation at NexusHealth.

"We wanted to develop a way to continuously monitor for heart injuries without requiring repeated blood draws."

The wearable device uses microscopic polymer needles that penetrate just beneath the skin, without reaching nerves or blood vessels. The microneedles collect interstitial fluid, the liquid that surrounds cells, and deliver it to a biosensor that's able to continuously track cardiac troponin levels over several days.

While continuous monitoring technology already exists for biomarkers such as glucose, proteins are much harder to track continuously. Cardiac troponin is present at very low concentrations in bloodstream and becomes even more diluted in the fluid beneath the skin.

"That's what makes this such an important advance. We're monitoring a protein that's present at very low levels and doing it continuously in living tissue," she says.

This device builds on previous work by Soleymani and the team in biosensing and aptamer engineering. Aptamers are short strands of DNA or RNA engineered to recognize specific biological targets.

Earlier versions of the technology monitored smaller molecules such as lactate. To detect proteins, researchers combined antibodies, which recognize proteins, and aptamers, which generate a measurable signal. The resulting sensor can continuously track biomarker levels over several days.

"A lot of different pieces had to come together for this work. We had to develop new sensing strategies, create a way to continuously refresh the sensor and integrate everything into a device patients could comfortably wear," says Soleymani.

The project brought together expertise from multiple institutions and disciplines. Researchers at the University of Waterloo developed the microneedle technology that made continuous sampling possible.

"Creating microneedles that can sample interstitial fluid comfortably and painlessly over extended periods and integrating them with sensing electrodes were a key steps towards continuous wearable sensing," says co-author Mahla Poudineh, now an associate professor at the NYU Tandon School of Engineering, whose group pioneered the use of these polymeric microneedles for wearable sensing.

At McMaster, co-author Bernardo Trigatti, professor in the Department of Biochemistry and Biomedical Sciences, and senior scientist in the Thrombosis and Atherosclerosis Research Institute of Hamilton Health Sciences and McMaster University, helped test the technology in living systems, an important step in demonstrating its potential for future clinical use.

"Testing the device in mouse models of heart disease was an important step toward understanding how it could eventually perform in clinical settings," he says.

The work builds on McMaster's internationally recognized leadership in myocardial injury after non-cardiac surgery, helping lay the foundation for technologies designed to identify patients at risk and enable earlier intervention.

The research team has received funding from the Canadian Institutes of Health Research (CIHR) to advance the technology through additional testing.

Researchers are also pursuing commercialization through Aptec Health, a startup founded to help bring the technology to patients.

While the immediate focus is post-surgical monitoring, the researchers see much broader possibilities across medicine. Many of the most important health changes happen between clinic visits, and technologies like this could provide a more continuous picture of what's happening in between appointments.

"The future of medicine is personalized, and personalized medicine needs data," says Soleymani.

For her, the project reflects the type of research that motivates her most: tackling difficult scientific challenges that could make a meaningful difference in people's lives.

"I like working on hard problems, and I like working on meaningful problems. This one has both."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.